封面
市場調查報告書
商品編碼
1600101

肝腎綜合症治療市場:按類型、治療方法和最終用戶分類 - 全球預測 2025-2030

Hepatorenal Syndrome Treatment Market by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Surgical Treatment, Therapeutics), End-User - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肝腎症候群治療市值為45.6億美元,預計2024年將達48億美元,複合年成長率為5.47%,預計到2030年將達到66.2億美元。

肝腎症候群 (HRS) 治療的重點是治療晚期肝病患者的一種複雜病症,其特徵是腎臟迅速惡化。這些包括血管收縮劑和白蛋白等藥物、透析治療、肝臟移植和新生技藥品。需要 HRS 治療是因為這種情況與高發病率和死亡率相關,早期有效的干涉對於改善患者的預後至關重要。 HRS治療適用於醫院、診所和研究機構,主要針對肝硬化或等待肝臟移植的患者。對 HRS 治療市場的見解突顯了全球肝病發病率的上升、治療方法的進步以及接受移植的患者數量不斷增加所推動的顯著成長。然而,它們面臨著治療成本上升、移植器官供應有限以及阻礙新治療方法核准過程的監管挑戰等限制。就商業機會而言,提供標靶治療解決方案的新型生物標記和治療方法市場的開拓前景。製藥公司和研究機構之間的合作研究可以加速藥物發現並加強治療策略。對研發和適應性臨床試驗設計的投資可以導致個人化治療計劃的製定,這也有可能改善患者特定的結果。鼓勵市場相關人員專注於生技藥品和再生醫學的創新,鑑於未滿足的需求,這提供了一條有希望的道路。我們面臨的挑戰是應對嚴格的監管環境並解決治療的可負擔性問題,這需要策略定價和更強力的衛生政策以確保廣泛獲得治療。認知到新興市場的多面性,公司正在探索與數位健康公司建立合作夥伴關係,以開發平台並利用資料來實現更好的疾病管理和患者對治療方法的依從性並改善健康結果。

主要市場統計
基準年[2023] 45.6億美元
預測年份 [2024] 48億美元
預測年份 [2030] 66.2億美元
複合年成長率(%) 5.47%

市場動態:快速發展的肝腎症候群治療市場的關鍵市場洞察

供需的動態交互作用正在改變肝腎綜合症治療市場。透過了解這些不斷變化的市場動態,公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,並了解消費行為及其對製造成本的影響,並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 肝腎綜合症盛行率增加
    • 快速通道和孤兒藥指定的增加
    • 提高疾病意識和患者支持計劃
  • 市場限制因素
    • 處理成本高,產品召回事故頻傳
  • 市場機會
    • 增加尖端技術的研發
    • 增加專注於創新 HRS 治療的生物創投公司的資金和創業投資
  • 市場挑戰
    • 與藥物使用相關的副作用和風險

波特五力:駕馭肝腎症候群治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢,解決弱點並避免潛在的挑戰,從而確保更強大的市場地位。

PESTLE分析:了解肝腎症候群治療市場的外部影響

外部宏觀環境因素在塑造肝腎症候群治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肝腎症候群治療市場的競爭狀況

肝腎綜合症治療市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣肝腎症候群治療市場供應商的績效評估

FPNV定位矩陣是評估肝腎症候群治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商,從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商,並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製肝腎綜合症治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說,對肝腎症候群治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標,公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰,利用新的商機,並取得長期成功。

本報告對市場進行了全面分析,涵蓋關鍵重點領域:

1. 市場滲透率:對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓:辨識新興市場的成長機會,評估現有領域的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:徹底分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,以幫助相關人員做出明智的決策:

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品、區隔市場和地區提供最佳投資機會?

3.塑造市場的主要技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肝腎綜合症盛行率增加
      • 簡審類和孤兒藥指定的增加
      • 擴大疾病意識和患者支持計劃
    • 抑制因素
      • 高額處理成本和產品召回事件
    • 機會
      • 加強研發,融入先進技術
      • 增加對專注於創新 HRS 治療的生物技術新興企業的資金和創業投資
    • 任務
      • 與藥物使用相關的副作用和風險
  • 市場區隔分析
    • 治療:持續創新以提高手術介入的有效性和治療結果
    • 最終用戶:醫院和診所提供全面的醫療保健解決方案和服務
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肝腎症候群治療市場:依類型

  • 1型肝腎綜合症
  • 2型肝腎綜合症

第7章肝腎症候群治療市場(依治療)

  • 手術治療
    • 肝臟移植
    • 腎臟替代治療
    • 手術分流術
  • 治療藥物
    • 甘加壓素
    • 盧卡辛
    • 特爾里瓦茲

第8章肝腎症候群治療市場:依最終用戶分類

  • 學術研究所
  • 門診手術中心
  • 醫院/診所

第9章北美及南美肝腎症候群治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太肝腎症候群治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲/中東/非洲肝腎症候群治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
    • Mallinckrodt在SCCM 2023會議上展示TERLIVAZ改善肝腎症候群的重要研究成果
    • FDA核准首個治療肝腎症候群快速腎衰竭的藥物
  • 戰略分析和建議

公司名單

  • Aetna Inc.
  • Baxter International Inc
  • Becton, Dickinson and Company
  • Biocon Limited
  • BioVie Inc
  • Cadila Healthcare Limited
  • Cumberland Pharmaceuticals Inc
  • Edwards Lifesciences Corporation
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Mallinckrodt Inc
  • Medtronic plc
  • Neovii Pharmaceuticals AG
  • Novartis International AG
  • Orphan Therapeutics, LLC
  • PharmaIN Corporation
  • Samarth Life Sciences Pvt Ltd.
  • Swastik Life Sciences
  • United Biotech Pvt Ltd.
Product Code: MRR-035DA3C63700

The Hepatorenal Syndrome Treatment Market was valued at USD 4.56 billion in 2023, expected to reach USD 4.80 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 6.62 billion by 2030.

Hepatorenal syndrome (HRS) treatment is focused on managing a complex condition characterized by rapid kidney deterioration in individuals with advanced liver disease. The scope includes pharmaceutical therapies such as vasoconstrictors and albumin, dialysis modalities, liver transplants, and emerging biologics. The necessity of HRS treatment arises due to the condition's association with high morbidity and mortality rates, making early and effective intervention critical in improving patient outcomes. Its application spans across hospital settings, clinics, and research institutions, primarily targeting patients with conditions like cirrhosis and those awaiting liver transplants. Insights into the HRS treatment market highlight substantial growth propelled by an increase in liver diseases globally, advancements in therapeutic methods, and a growing transplant recipient population. However, the market faces limitations, such as the high cost of treatment, limited availability of transplant organs, and regulatory challenges that hinder approval processes for new therapies. In terms of opportunity, the market holds potential in the development of novel biomarkers and therapies that offer targeted treatment solutions. Collaborations between pharmaceutical companies and research organizations can accelerate drug discovery and enhance therapeutic strategies. Investment in R&D and adaptive clinical trial designs could also lead to the development of personalized treatment plans, improving patient-specific outcomes. Market players are recommended to focus on innovation in biologics and regenerative medicines, which present promising avenues given the unmet clinical needs. Challenges lay in navigating the stringent regulatory landscapes and addressing the affordability of treatments, which require strategic pricing and enhanced healthcare policies to facilitate widespread accessibility. Recognizing the multidimensional nature of the market, businesses should also explore partnerships with digital health companies to develop platforms that allow for better disease management and patient adherence to therapy regimens, leveraging data for improved health outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 4.56 billion
Estimated Year [2024] USD 4.80 billion
Forecast Year [2030] USD 6.62 billion
CAGR (%) 5.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatorenal Syndrome Treatment Market

The Hepatorenal Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of hepatorenal syndrome
    • Increasing fast track and orphan drug designations
    • Growing disease awareness & patient support programs
  • Market Restraints
    • High treatment costs, and product recall incidents
  • Market Opportunities
    • Increasing research & development to incorporate advanced technologies
    • Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
  • Market Challenges
    • Side-effects and risks related to drug usage

Porter's Five Forces: A Strategic Tool for Navigating the Hepatorenal Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatorenal Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hepatorenal Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatorenal Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hepatorenal Syndrome Treatment Market

A detailed market share analysis in the Hepatorenal Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatorenal Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatorenal Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatorenal Syndrome Treatment Market

A strategic analysis of the Hepatorenal Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatorenal Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Baxter International Inc, Becton, Dickinson and Company, Biocon Limited, BioVie Inc, Cadila Healthcare Limited, Cumberland Pharmaceuticals Inc, Edwards Lifesciences Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Mallinckrodt Inc, Medtronic plc, Neovii Pharmaceuticals AG, Novartis International AG, Orphan Therapeutics, LLC, PharmaIN Corporation, Samarth Life Sciences Pvt Ltd., Swastik Life Sciences, and United Biotech Pvt Ltd..

Market Segmentation & Coverage

This research report categorizes the Hepatorenal Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Type 1 Hepatorenal Syndrome and Type 2 Hepatorenal Syndrome.
  • Based on Treatment, market is studied across Surgical Treatment and Therapeutics. The Surgical Treatment is further studied across Liver Transplantation, Renal Replacement Therapy, and Surgical Shunting. The Therapeutics is further studied across Glypressin, Lucassin, and Terlivaz.
  • Based on End-User, market is studied across Academic & Research Institutes, Ambulatory Surgical Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of hepatorenal syndrome
      • 5.1.1.2. Increasing fast track and orphan drug designations
      • 5.1.1.3. Growing disease awareness & patient support programs
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs, and product recall incidents
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research & development to incorporate advanced technologies
      • 5.1.3.2. Increased funding and venture capital for biotech start-ups focusing on innovative HRS treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects and risks related to drug usage
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Ongoing innovations to improve the efficacy and treatment outcomes of surgical interventions
    • 5.2.2. End-User: Availability of comprehensive healthcare solutions and services in hospitals and clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hepatorenal Syndrome Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Type 1 Hepatorenal Syndrome
  • 6.3. Type 2 Hepatorenal Syndrome

7. Hepatorenal Syndrome Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Surgical Treatment
    • 7.2.1. Liver Transplantation
    • 7.2.2. Renal Replacement Therapy
    • 7.2.3. Surgical Shunting
  • 7.3. Therapeutics
    • 7.3.1. Glypressin
    • 7.3.2. Lucassin
    • 7.3.3. Terlivaz

8. Hepatorenal Syndrome Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Hospitals & Clinics

9. Americas Hepatorenal Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hepatorenal Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hepatorenal Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Mallinckrodt Announces Key Study Results on TERLIVAZ for Hepatorenal Syndrome Reversal at SCCM 2023 Congress
    • 12.3.2. FDA Approves First-Ever Treatment for Rapid Kidney Failures in Hepatorenal Syndrome
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aetna Inc.
  • 2. Baxter International Inc
  • 3. Becton, Dickinson and Company
  • 4. Biocon Limited
  • 5. BioVie Inc
  • 6. Cadila Healthcare Limited
  • 7. Cumberland Pharmaceuticals Inc
  • 8. Edwards Lifesciences Corporation
  • 9. F. Hoffmann-La Roche AG
  • 10. GlaxoSmithKline plc
  • 11. Mallinckrodt Inc
  • 12. Medtronic plc
  • 13. Neovii Pharmaceuticals AG
  • 14. Novartis International AG
  • 15. Orphan Therapeutics, LLC
  • 16. PharmaIN Corporation
  • 17. Samarth Life Sciences Pvt Ltd.
  • 18. Swastik Life Sciences
  • 19. United Biotech Pvt Ltd.

LIST OF FIGURES

  • FIGURE 1. HEPATORENAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEPATORENAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEPATORENAL SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 1 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE 2 HEPATORENAL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL SHUNTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY GLYPRESSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY LUCASSIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TERLIVAZ, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM HEPATORENAL SYNDROME TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. HEPATORENAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. HEPATORENAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023